What Is GHRP-2?
GHRP-2 is a laboratory-made peptide that activates the ghrelin receptor, a signalling protein involved in growth hormone release, appetite and several other body systems. It is also called pralmorelin and contains six amino-acid-like building blocks, so it is described as a synthetic hexapeptide.
GHRP-2 has a more substantial human research record than many compounds sold as research peptides. A defined pralmorelin medicine is used in Japan as a one-time diagnostic test of the body's ability to release growth hormone. That narrow diagnostic use does not make GHRP-2 an approved treatment in the United States, and it does not establish the muscle-building, fat-loss, recovery or anti-ageing claims attached to it online.
What exactly is GHRP-2?
The name means growth hormone-releasing peptide 2. Growth hormone is a 191-amino-acid protein released by the pituitary gland at the base of the brain. A secretagogue is a substance that prompts a gland to release something it already makes. GHRP-2 is therefore a growth hormone secretagogue, not growth hormone itself.
Its international non-proprietary name is pralmorelin. Earlier research names include KP-102, KP-102D, KP-102LN and GPA-748. These names usually refer to the same active peptide, although salts and finished formulations may differ.
The commonly reported sequence is D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. D-2-Nal is D-2-naphthylalanine, an artificial amino-acid analogue with a naphthalene ring. D-Ala and D-Phe are mirror-image versions of alanine and phenylalanine. The final NH2 indicates an amidated end rather than the free acid found at the end of many ordinary peptides.
Those features matter because a six-residue chain containing D-amino acids and an aromatic artificial residue is not simply a short piece cut from a human hormone. It was designed chemically to resist rapid breakdown and activate a particular receptor.
Is GHRP-2 growth hormone, GHRH or a steroid?
No. GHRP-2 is not growth hormone, growth hormone-releasing hormone or an anabolic steroid.
Growth hormone-releasing hormone, shortened to GHRH, is a natural 44-amino-acid signal made in the hypothalamus. It activates the GHRH receptor. Compounds such as sermorelin, tesamorelin and CJC-1295 act mainly through that route.
GHRP-2 acts at the growth hormone secretagogue receptor, usually shortened to GHS-R1a and commonly called the ghrelin receptor. Ghrelin is a natural hormone made mainly in the stomach. The two receptor systems can reinforce one another, which is why GHRP-2 and GHRH produced larger growth hormone responses together in laboratory and human experiments.
Anabolic steroids are testosterone-related compounds that act through androgen receptors. GHRP-2 has a different structure and target. Calling it non-steroidal does not make it safe or prove that changing the growth hormone and insulin-like growth factor 1 system improves health or performance.
How does the normal ghrelin and growth hormone system work?
The hypothalamus is a hormone-controlling region of the brain. It sends GHRH to the pituitary and also releases somatostatin, a signal that restrains growth hormone release. The balance changes throughout the day, producing pulses rather than a steady concentration.
The pituitary releases growth hormone into the bloodstream. Growth hormone acts directly on some tissues and also prompts the liver and other tissues to make insulin-like growth factor 1, normally shortened to IGF-1. IGF-1 is involved in normal growth, metabolism and tissue maintenance. It is also part of a feedback system that limits further growth hormone release.
Ghrelin adds another layer. It is made mainly by the stomach, rises in relation to fasting and meal timing, and can influence appetite, stomach movement, glucose regulation and growth hormone secretion. Acylated ghrelin is the form carrying a fatty-acid modification that allows it to activate GHS-R1a.
GHRP-2 activates the same receptor without being a copy of ghrelin. Receptors are proteins that detect a signal and start activity inside a cell. An agonist is a molecule that activates a receptor. The ghrelin receptor is present in the pituitary and several brain regions, which helps explain why GHRP-2 can affect both growth hormone and appetite.
The response still depends on the wider system. Age, body fat, fasting, sex hormones, natural GHRH, somatostatin tone and pituitary health can all change the size of the growth hormone response. A strong response in one controlled test cannot be assumed for another person, product, route or pattern of exposure.
What is GHRP-2 made from?
The active molecule contains six linked residues. Several are familiar amino acids, but their orientation or side chains have been changed:
- D-alanine begins the sequence.
- D-2-naphthylalanine is an artificial aromatic residue.
- L-alanine is the third residue.
- L-tryptophan is the fourth residue.
- D-phenylalanine is the fifth residue.
- L-lysine is the sixth residue.
- The end is amidated, shown by NH2.
Human proteins are normally built almost entirely from L-amino acids. A D-amino acid is a mirror-image form. Many enzymes that cut ordinary peptides recognise L-amino-acid arrangements more readily, so D-residues can make a synthetic peptide harder to break down. They also make identity testing more demanding because ordinary mass measurement may not reveal whether the orientation is correct.
A finished material may be described as pralmorelin free base, acetate, dihydrochloride or another salt. A salt includes associated ions that balance charge and can affect mass, solubility, analysis and formulation. Evidence from a licensed Japanese pralmorelin product cannot automatically be assigned to every product carrying the GHRP-2 name.
How is GHRP-2 synthesised and manufactured?
GHRP-2 can be made by solid-phase peptide synthesis. A protected first building block is attached to an insoluble resin. The remaining protected amino-acid derivatives are joined one at a time. Each cycle removes a temporary protective group, activates the next residue and forms a peptide bond.
The raw materials include protected L- and D-amino acids, protected D-2-naphthylalanine, a resin, coupling reagents, bases, solvents and chemicals needed to produce the terminal amide. These are chemical raw materials. GHRP-2 is not extracted from human pituitary or stomach tissue.
After assembly, strong reagents release the peptide from the resin and remove most remaining protective groups. The crude mixture can contain incomplete chains, deletion sequences, residues with the wrong orientation, oxidised tryptophan products, residual solvents and material carrying unwanted modifications. Preparative high-performance liquid chromatography, shortened to HPLC, can separate the main product from many impurities.
Analytical HPLC estimates the proportions of separated components. Mass spectrometry measures mass-to-charge patterns and supports confirmation of the expected molecular mass. More detailed methods may be needed to verify sequence and stereochemistry, meaning the three-dimensional orientation of the residues.
Manufacture for human administration requires more than a headline purity percentage. It requires controlled raw materials, validated impurity limits, testing for residual solvents and counterions, stability studies and control of aggregates. An aggregate is a cluster of peptide molecules. Injectable products also require validated sterility, endotoxin and particle controls. Endotoxins are inflammatory bacterial components that can remain even when no living bacterium is detected.
FDA specifically highlights aggregation, peptide-related impurities and the unnatural amino acid in GHRP-2 as reasons why compounded injectable and nasal products may create immune-response and characterisation risks.
When was GHRP-2 first documented?
GHRP-2 grew out of a research programme that began with opioid-like peptides but moved into a different receptor system.
In 1981, researchers reported that modified enkephalin peptides could stimulate growth hormone release from rat pituitary tissue. Enkephalins are natural peptides involved in opioid signalling, but the growth hormone-releasing activity of the redesigned compounds did not depend on ordinary opioid effects.
By 1984, a six-residue compound later known as GHRP-6 had been described in cell and animal experiments. Researchers then changed its sequence to improve potency and oral activity. KP-102, later called GHRP-2 or pralmorelin, emerged during this optimisation work in the late 1980s and early 1990s.
The receptor activated by these compounds was identified before its natural hormone. The growth hormone secretagogue receptor was cloned in 1996. Ghrelin was isolated from the stomach and identified as its natural ligand in 1999. Ligand means a molecule that binds to a receptor.
GHRP-2 entered human endocrine, diagnostic and paediatric studies during the 1990s. Japan later approved pralmorelin as a diagnostic agent for severe growth hormone deficiency. Research continued into appetite, critical illness and longer exposure, but no broad treatment approval followed in the United States or United Kingdom.
| Period | Development |
|---|---|
| 1981 | Modified enkephalin-derived peptides were reported to release growth hormone in pituitary experiments |
| 1984 | The six-residue GHRP-6 sequence was described in cell and animal research |
| Late 1980s to early 1990s | Sequence optimisation produced more potent compounds including KP-102, later called GHRP-2 |
| 1996 | Scientists cloned the growth hormone secretagogue receptor |
| 1999 | Ghrelin was identified as the receptor's natural hormone |
| 1990s to early 2000s | GHRP-2 was studied in endocrine tests, children, older adults and critically ill patients |
| 2004 | A development review described pralmorelin's diagnostic programme in Japan |
| 2007 | A 135-person study validated the GHRP-2 test against the insulin tolerance test |
| 2014 | A 48-week paediatric trial reported more endogenous growth hormone without useful growth promotion |
| 2023 | FDA placed injectable and nasal GHRP-2 on its 503B category of substances that may present significant safety risks |
| 2026 | GHRP-2 remained a Japanese diagnostic medicine rather than an approved general treatment |
How does GHRP-2 work?
GHRP-2 binds to GHS-R1a on pituitary cells and in the hypothalamus. At the pituitary, receptor activation raises calcium inside somatotrophs, the cells that store and release growth hormone. At the hypothalamic level, it can reinforce natural GHRH signalling and reduce some of somatostatin's restraining effect.
This route differs from direct GHRH-receptor activation. When researchers gave a GHRP and GHRH together, the growth hormone response could be greater than the sum expected from either alone. That is described as synergy. It shows that the two signals interact, but it does not establish a useful or safe treatment combination.
The ghrelin receptor is also connected with appetite-regulating networks involving neuropeptide Y and agouti-related peptide neurons. These are brain cells that promote feeding. Human feeding studies confirm that GHRP-2 can increase hunger and food intake.
GHRP-2 can also stimulate adrenocorticotropic hormone, shortened to ACTH, cortisol and prolactin under some experimental conditions. ACTH is a pituitary hormone that prompts the adrenal glands to release cortisol. Prolactin is best known for its role in milk production but has functions in both sexes. These additional hormone effects show that GHRP-2 is not perfectly selective for growth hormone.
What do we know about its duration?
Online descriptions often give GHRP-2 a precise half-life after subcutaneous exposure. The most clinically useful evidence does not support treating one popular number as universal.
Half-life is the time required for the measured amount of a compound in the body to fall by half. It depends on the chemical form, route, formulation, analytical method and population. The Japanese diagnostic literature focuses mainly on the growth hormone response after a defined intravenous test rather than on a complete concentration-time profile for every route.
In the diagnostic validation study, serum growth hormone peaked within 60 minutes after a 100-microgram intravenous administration. That timing describes the hormone response, not the peptide's half-life. A separate anti-doping study detected GHRP-2, its free acid and a short metabolite in urine for up to 47 hours after a controlled exposure. A detection window is not the same as biological activity.
The reasonable conclusion is that free GHRP-2 produces a comparatively brief signal rather than the multi-day exposure of albumin-binding CJC-1295 DAC. Precise claims for a nasal, subcutaneous or unverified product require direct pharmacokinetic evidence for that form.
What human research exists?
The human record can be divided into five areas:
- One-time endocrine testing to measure pituitary growth hormone reserve.
- Short studies of growth hormone, IGF-1 and other hormone responses.
- Feeding studies that measured hunger and food intake.
- Paediatric studies asking whether repeated exposure promoted growth.
- Critical-illness research using continuous GHRP-2 alone or with other releasing hormones.
This is a wider evidence base than a cell-only or animal-only peptide. It still does not amount to evidence for the main consumer claims. Most experiments measured hormone concentrations, appetite or diagnostic accuracy. They did not test useful muscle gain, fat loss, athletic performance, injury healing or lifespan.
The evidence also comes from several different formulations and routes. A licensed diagnostic injection, a continuous research infusion, an intranasal spray and an unverified research-market vial are not interchangeable.
What did the Japanese diagnostic research show?
The best-established use is a provocative test. Provocative means that a substance is given once to challenge a hormone system and measure its response.
A 2007 validation study enrolled 77 healthy participants and 58 patients whose severe growth hormone deficiency had already been identified by an insulin tolerance test. The insulin tolerance test deliberately lowers blood glucose under medical supervision and measures the growth hormone response. It can be unsafe for some people, which created demand for an alternative.
After an overnight fast, each participant received 100 micrograms of GHRP-2 intravenously and had blood sampled for two hours. The average peak growth hormone concentration was 84.6 micrograms per litre in the healthy group and 1.36 micrograms per litre in the patient group. The response occurred within 60 minutes and repeated testing showed favourable reproducibility.
The researchers proposed a cut-off for identifying severe deficiency. A cut-off is a measurement selected to separate likely positive and negative results. It is not a target hormone level for treatment.
Japan uses pralmorelin for this diagnostic purpose. The approval belongs to a defined medicine, administration setting and interpretation procedure. It does not approve repeated use for physique, ageing, appetite or recovery.
Documented administration levels in human research
The values below identify published experiments. They are included to explain what the evidence can and cannot show. They are not personal doses, administration instructions or a protocol.
| Study | Participants | Documented research exposure | Main question |
|---|---|---|---|
| Diagnostic validation | 77 healthy people and 58 patients | One 100-microgram intravenous administration after fasting | Could the growth hormone response identify severe deficiency? |
| Five-day response study | Nine healthy young adults | 100 micrograms subcutaneously once daily for five days | Did the growth hormone response weaken and did IGF-1 rise? |
| Thirty-day older-adult study | 17 older adults in the extended-exposure group | Continuous subcutaneous infusion at 1 microgram per kilogram per hour for 30 days | Could repeated signalling sustain growth hormone and IGF-1 changes? |
| Lean-men feeding study | Seven healthy men | Subcutaneous infusion at 1 microgram per kilogram per hour during a controlled meal experiment | Did food intake change compared with saline? |
| Lean and obese feeding study | 10 lean and nine obese adults | Randomised infusions at 0.1 or 1 microgram per kilogram per hour, or placebo, for 270 minutes | Was food intake affected by experimental level or obesity? |
| Eight-month paediatric study | Six prepubertal children with growth hormone deficiency | Stepwise subcutaneous levels of 0.3, 1 and 3 micrograms per kilogram per day | Did longer exposure improve growth hormone secretion or growth? |
| Forty-eight-week paediatric trial | 126 prepubertal short children with growth hormone deficiency | Placebo or intranasal 50 to 200 micrograms twice daily, assigned partly by body weight | Did raising endogenous growth hormone promote useful linear growth? |
Different routes produce different exposure. Continuous infusion is not equivalent to a single injection, and a nasal spray is not equivalent to a licensed intravenous diagnostic product. Several studies involved children or vulnerable critically ill patients and cannot be repurposed as adult self-use evidence.
What did the appetite studies find?
GHRP-2 has direct human evidence for increasing food intake. This is one of the few effects that participants could notice rather than a laboratory biomarker alone.
In a randomised, double-blind crossover study, seven healthy lean men received GHRP-2 or saline during separate visits. Crossover means that each participant experienced both conditions and acted as his own comparison. During the GHRP-2 visit, the men ate 35.9% more at a buffet meal on average. Every participant increased intake when the results were adjusted for body weight.
A second study enrolled 19 weight-stable adults, including 10 lean and nine obese participants. Each received a high experimental infusion, a level one-tenth as large and placebo in random order across three visits. The lower level increased food intake by 10.2% compared with placebo, while the higher level increased it by 33.5%. The obese and lean groups both responded.
These were short controlled feeding experiments. They show an acute appetite and food-intake effect. They do not show healthy long-term weight gain, treatment of a disease, improved muscle growth or acceptable long-term safety. Increased appetite could be unwanted for someone concerned about body weight or glucose control.
Does repeated exposure keep producing the same response?
Not always. A five-day study gave 100 micrograms subcutaneously once daily to nine healthy young adults. Average peak growth hormone fell from 83 micrograms per litre on day 1 to 59 on day 3 and 51 on day 5. The area under the growth hormone curve also declined. Area under the curve summarises total measured exposure over time.
The response did not disappear, but it weakened significantly. IGF-1 did not increase across the five days. Osteocalcin, a marker connected with bone turnover, increased, but a marker change is not proof of stronger bone or reduced fracture risk.
A different study used continuous exposure for 30 days in 17 older adults. It reported sustained increases in pulsatile growth hormone, IGF-1 and several IGF-binding proteins. The 30-day result shows that one continuous experimental arrangement can maintain biomarker changes. It does not cancel the attenuation seen with once-daily administrations, because route, pattern, population and study design differed.
Together, the studies show why simple claims about avoiding desensitisation are unreliable. Desensitisation means that a receptor system produces a smaller response after repeated stimulation. The degree depends on the exposure pattern and the outcome being measured.
Did GHRP-2 help children grow?
The paediatric record shows why a hormone response and a clinical outcome must be kept separate.
An early study followed six prepubertal children with growth hormone deficiency through stepwise subcutaneous levels over eight months. The programme measured overnight growth hormone secretion and growth. Its small size and changing levels made firm conclusions difficult.
A later trial was much larger. It enrolled 126 prepubertal short children diagnosed with growth hormone deficiency. Participants received placebo or one of two intranasal GHRP-2 levels twice daily for 48 weeks. The spray raised endogenous growth hormone, but the investigators concluded that the increase did not promote useful growth.
The study is especially relevant to claims that stimulating the body to release its own growth hormone must be more effective or physiological than providing an approved medicine. In this trial, the biological signal moved, but the intended outcome did not.
These findings do not support paediatric use outside specialist care. Children require separate development programmes, growth monitoring and long-term safety assessment. An unapproved research product cannot inherit the controls of the trial material or the Japanese diagnostic medicine.
What did the critical-illness studies investigate?
During prolonged critical illness, growth hormone pulses, thyroid signalling and metabolism can become abnormal. Researchers studied continuous GHRP-2, sometimes with GHRH, thyrotropin-releasing hormone or gonadotrophin-releasing hormone, to see whether several pituitary systems could be reactivated.
These experiments involved small groups of patients who had already been critically ill for weeks. They measured hormone patterns, nitrogen metabolism and laboratory markers. Some combinations produced endocrine and metabolic changes. A change in a marker did not establish improved survival, faster discharge or long-term recovery.
Interpretation is made harder because GHRP-2 was often combined with another releasing hormone. A result from GHRP-2 plus thyrotropin-releasing hormone cannot be attributed to GHRP-2 alone.
FDA notes reports of increased insulin requirements, infection, pancreatitis and deaths among critically ill study participants exposed to GHRP-2, while also stating that causality has not been established. Critically ill patients already have a high risk of these outcomes, so the studies cannot prove that GHRP-2 caused each event. They also cannot be used as reassurance for unsupervised use.
Does GHRP-2 affect cortisol or prolactin?
Yes, it can. GHRP-2 is often presented as a cleaner or more selective growth hormone signal than older GHRPs. The human evidence does not support calling it completely selective.
Studies have reported increases in ACTH, cortisol and prolactin after acute exposure. The size of the effect depends on the experimental level, timing, health of the participants and comparison compound. Cortisol is involved in stress responses, blood pressure, immune activity and glucose regulation. Persistent excess is not desirable. A brief laboratory rise does not show that chronic disease will develop, but it is a reason not to describe the peptide as acting only on growth hormone.
The Japanese GHRP-2 test has also been studied as a possible way to assess the adrenal axis because the ACTH and cortisol response may reveal some forms of secondary adrenal insufficiency. That is a supervised diagnostic research use, not evidence that GHRP-2 supports healthy adrenal function.
What claimed benefits are supported?
| Claim | What the human evidence shows | What remains unproven |
|---|---|---|
| Releases growth hormone | Repeated small studies and diagnostic work show a rapid response | Whether an unverified product produces the same response safely |
| Diagnoses severe growth hormone deficiency | A defined test is used in Japan and was validated against the insulin tolerance test | Diagnostic approval outside that product, procedure and jurisdiction |
| Raises IGF-1 | Continuous 30-day exposure raised IGF-1 in older adults; five daily administrations did not | A consistent response across routes and useful health benefit |
| Increases appetite | Two controlled human feeding studies found more food intake | Safe long-term treatment of undernutrition or illness |
| Builds muscle | No controlled GHRP-2 trial established useful muscle or strength gain | Magnitude, durability and risk of any body-composition effect |
| Reduces fat | No controlled treatment trial established fat loss | Whether appetite stimulation could oppose the claim |
| Improves recovery | No controlled injury or rehabilitation trial established faster recovery | Pain, tissue healing, function and return to activity |
| Improves sleep | No robust GHRP-2 treatment trial established better sleep or daytime function | Sleep quality, architecture and long-term effects |
| Reverses ageing | Older-adult studies changed hormone biomarkers | Healthspan, independence, disease risk and longevity |
A biomarker is a measurable biological sign. Growth hormone and IGF-1 are biomarkers of pathway activity. They can show that a compound reached a biological target without showing that a person became stronger, leaner, healthier or less likely to be injured.
The Orentra research methodology therefore gives greater weight to controlled clinical outcomes than to hormone peaks or mechanistic plausibility.
What do cell and animal studies add?
Cell and animal work has examined inflammation, arthritis, heart injury and other stress models. Some rodent studies reported anti-inflammatory or tissue-protective effects after GHRP-2. These experiments help researchers explore whether ghrelin-receptor signalling has actions beyond growth hormone.
They do not establish a recovery medicine. Rodent disease models use controlled injuries, defined research material and exposure levels that may not match human biology. An improvement in an inflammatory marker or tissue sample does not show that a person heals faster or returns to activity sooner.
Some effects may also be partly independent of growth hormone. That makes the science interesting, but it adds uncertainty rather than proving a broad benefit. A compound acting in several systems may create additional risks as well as possible research opportunities.
What is known about safety?
The most reliable short-term information comes from defined clinical research and the Japanese diagnostic setting. Acute effects may include hunger, flushing, warmth, changes in hormone concentrations and local effects associated with the route used. The published literature is not large enough to estimate uncommon harms across a broad population.
Important areas of uncertainty include:
- glucose control and insulin requirements;
- repeated cortisol or prolactin stimulation;
- fluid retention and other effects associated with raising the growth hormone and IGF-1 axis;
- pituitary responses during prolonged or repeated exposure;
- effects on an existing tumour, because growth hormone and IGF-1 participate in cell growth;
- immune reactions to aggregates or peptide impurities;
- infection, endotoxin or concentration errors in an injectable product;
- use in children, pregnancy, cancer, diabetes or critical illness.
FDA reports serious events in critically ill study participants, including deaths, infection, pancreatitis and increased insulin needs, but says causality was not established. The correct reading is neither that GHRP-2 caused all events nor that it has been cleared of risk. The studies were conducted in a highly vulnerable population and do not provide adequate long-term safety evidence.
Japan's approval of a one-time diagnostic product does not answer the safety of repeated unsupervised exposure. Frequency and duration can change risk even when the active molecule is the same.
What is the regulatory position?
Pralmorelin is used in Japan as a diagnostic agent for severe growth hormone deficiency. It is not a Japanese approval for bodybuilding, fat loss, anti-ageing, recovery or long-term growth hormone stimulation.
GHRP-2 is not an FDA-approved medicine. FDA's May 2026 503A list places GHRP-2 in category 3, meaning it was nominated for traditional pharmacy compounding without adequate supporting information for evaluation. Under the separate 503B interim policy for outsourcing facilities, injectable and nasal GHRP-2 appears in category 2, which covers substances that may present significant safety risks.
Section 503A and 503B are parts of US compounding law. A place on an interim category list is not drug approval. Compounded products are not reviewed in advance for safety, effectiveness and manufacturing consistency in the same way as an FDA-approved medicine.
FDA cites possible immune reactions from aggregation and impurities, difficulty characterising the unnatural amino acid and reports of serious events in critically ill participants. These concerns apply to compounded products and do not mean every event has been proved to result from the peptide.
Is GHRP-2 prohibited in sport?
Yes. The World Anti-Doping Agency, shortened to WADA, names GHRP-2 and pralmorelin in section S2.2.4 of the 2026 Prohibited List. It is prohibited at all times, both in and out of competition, for athletes covered by the World Anti-Doping Code.
Anti-doping laboratories can detect the intact peptide and characteristic metabolites using liquid chromatography and mass spectrometry. Chromatography separates substances in a sample. Mass spectrometry helps identify them from mass-to-charge patterns. Researchers have detected GHRP-2-related material in controlled administration studies and in samples from athletes.
A medicine being approved for a diagnostic purpose in one country does not remove the anti-doping prohibition. An athlete requiring a prohibited diagnostic substance would need to follow the relevant medical and therapeutic-use procedures.
Why does product identity matter?
The clinical literature used defined research or pharmaceutical material. A vial carrying the same name is not automatically equivalent.
Identity questions include:
- Is the sequence correct at all six positions?
- Are the D-amino acids in the intended orientation?
- Is the naphthylalanine residue correct?
- Is the C-terminal amide present?
- Which salt or counterion is present?
- Are deletion sequences, oxidation products or aggregates controlled?
- Does the vial contain the stated quantity?
- Has sterility and endotoxin control been demonstrated for the finished product?
A high HPLC purity number cannot answer every question. It may show that one component dominates a sample without proving complete sequence, stereochemistry, biological activity, sterility or acceptable impurity limits.
How does GHRP-2 compare with related compounds?
| Compound | Main receptor route | Key evidence | Regulatory position |
|---|---|---|---|
| GHRP-2 / pralmorelin | Ghrelin receptor | Diagnostic validation, short hormone studies and controlled appetite studies | Diagnostic medicine in Japan; not FDA approved |
| GHRP-6 | Ghrelin receptor | Human endocrine studies, small pharmacokinetic study and combination stroke trials | Unapproved in the US; no established general treatment |
| Ipamorelin | Ghrelin receptor | Limited early pharmacology and postoperative bowel-recovery development | Unapproved |
| Hexarelin | Ghrelin receptor | Small human endocrine studies with ACTH, cortisol and prolactin effects | Unapproved |
| CJC-1295 DAC | GHRH receptor | Small studies of prolonged growth hormone and IGF-1 changes | Unapproved |
| Mod GRF 1-29 | GHRH receptor | No direct clinical programme located for the exact marketed form | Unapproved |
| Tesamorelin | GHRH receptor | Controlled clinical trials for a defined condition | Used in approved EGRIFTA medicines for a specific indication |
GHRP-2 and GHRP-6 are often compared as if one were a stronger version and the other an appetite version. The evidence is more complicated. GHRP-2 has direct controlled human feeding evidence and a Japanese diagnostic use. GHRP-6 has extensive endocrine-provocation research and recent stroke trials only as part of an epidermal growth factor combination. No head-to-head treatment trial establishes which is better for a consumer goal.
Combining a GHRP with a GHRH analogue is promoted online because the signals can act synergistically. This guide does not provide stacking or combination advice. Synergy in a hormone test does not prove improved health, and it may increase exposure and risk.
What would stronger treatment evidence require?
The first requirement would be a precisely defined active ingredient and formulation. Researchers would need to confirm sequence, stereochemistry, salt, impurities, aggregation, stability and, for an injectable product, sterility and endotoxin control.
An early study would need to measure GHRP-2 concentrations and hormone responses across time while monitoring glucose, insulin, cortisol, prolactin, blood pressure, fluid balance and immune responses. Repeated-exposure work would need to examine attenuation and recovery of receptor response.
A later trial would need a specific medical condition and a meaningful outcome. A muscle study would require validated muscle mass, strength and function rather than growth hormone alone. An injury study would need pain, healing, return to activity and re-injury outcomes. An appetite study in undernutrition would need weight quality, function and clinical recovery, not just one larger meal.
Longer follow-up would be needed for glucose regulation, pituitary effects, immune reactions and tumour-related safety. Evidence from a one-time Japanese diagnostic test cannot replace that development programme.
Frequently asked questions
Is GHRP-2 the same as pralmorelin?
Yes. Pralmorelin is the international non-proprietary name for GHRP-2. KP-102 and GPA-748 are earlier development names. Finished products and salt forms can still differ.
Is GHRP-2 an approved medicine?
A defined pralmorelin product is used in Japan as a diagnostic test for severe growth hormone deficiency. GHRP-2 is not FDA approved, and the Japanese diagnostic approval does not cover muscle gain, fat loss, anti-ageing or long-term treatment.
Is GHRP-2 growth hormone?
No. It activates the ghrelin receptor and prompts the pituitary to release growth hormone. Growth hormone itself is a different 191-amino-acid protein.
How many amino acids are in GHRP-2?
It is described as a hexapeptide because it contains six linked residues. Several are D-amino acids or artificial analogues rather than the ordinary L-amino acids used in human proteins.
Does GHRP-2 increase appetite?
Controlled short-term studies found that it increased hunger and food intake. One seven-man crossover study reported 35.9% more food intake during GHRP-2 exposure than during saline.
Does GHRP-2 build muscle or reduce fat?
No controlled clinical trial has established useful muscle gain, strength improvement or fat loss. Raising growth hormone or IGF-1 is a biomarker effect, not proof of those outcomes.
Does GHRP-2 raise IGF-1?
It can under some exposure patterns. A 30-day continuous-infusion study in older adults raised IGF-1, while a five-day once-daily study did not. The response cannot be assumed across products and routes.
Can the response weaken with repeated exposure?
Yes. In nine healthy young adults, the growth hormone response became significantly smaller across five days of once-daily experimental exposure, although it did not disappear.
Did GHRP-2 help children grow?
A 48-week trial raised endogenous growth hormone but did not establish useful growth promotion. This does not support paediatric use outside specialist research or approved care.
What is the half-life of GHRP-2?
No single popular number should be treated as established for every route and formulation. Diagnostic studies describe the hormone response, while urine detection studies describe detectability rather than active duration.
Are the administration levels in this guide recommendations?
No. They identify published experiments and help explain the evidence. They are not personal dosing, preparation or administration advice.
Is compounded GHRP-2 FDA approved?
No. Compounded drugs are not FDA approved. FDA lists injectable and nasal GHRP-2 among compounded substances that may present significant safety risks.
Is GHRP-2 prohibited in sport?
Yes. WADA names GHRP-2 and pralmorelin among prohibited growth hormone-releasing peptides. The prohibition applies in and out of competition for covered athletes.
Sources
Research reviewed through September 2026.